Egr-1 expression during neointimal development in flow-associated pulmonary hypertension

Area of Science:

• Cardiovascular Research
• Pulmonary Hypertension Pathophysiology
• Molecular Biology

Background:

• Increased pulmonary blood flow is a key factor in neointimal formation in flow-associated pulmonary arterial hypertension (PAH).
• Early growth response protein 1 (Egr-1) was previously identified as upregulated in experimental end-stage PAH.

Purpose of the Study:

• To investigate the spatiotemporal expression of Egr-1 during the development of neointimal lesions in flow-associated PAH.
• To determine the role of Egr-1 in PAH pathogenesis.

Main Methods:

• Flow-associated PAH was induced in rats using monocrotaline and an aortocaval shunt.
• Egr-1 expression was analyzed using laser microdissection, quantitative real-time PCR, and immunohistochemistry at various time points.
• Egr-1 expression was also examined in a non-neointimal pulmonary hypertension model and in human PAH samples.

Main Results:

• Egr-1 mRNA levels increased one day after flow addition and in end-stage PAH, but not with monocrotaline alone.
• Egr-1 was initially expressed in endothelial cells post-flow addition, with protein expression increasing and localizing throughout the vessel wall during disease progression.
• PAH patients exhibited Egr-1 expression in vessels with medial hypertrophy, neointimal lesions, and plexiform lesions.

Conclusions:

• Egr-1 expression is dynamically regulated in response to increased pulmonary blood flow.
• Egr-1 is a potential key regulator in the development of pulmonary neointimal lesions associated with increased blood flow in PAH.